OR WAIT null SECS
Aprecia's compression-free 3DP manufacturing platform and Glatt’s multiparticulate technologies offer solutions to pharmaceutical dosage design challenges.
Glatt Pharmaceutical Services and Aprecia announced on Feb. 23, 2021 a joint effort to accelerate and expand the use of Glatt's multiparticulate technologies through Aprecia's ZipDose technology for 3DP manufacturing. The collaboration will advance manufacturing solutions for oral pharmaceutical design challenges that are not addressed by conventional oral solid-dosage manufacturing. The collaboration will initially target existing products for modified release brand-line extensions as well as new chemical entities through accelerated clinical development and patient-focused dosage forms.
"Aprecia has taken a complete approach for partnering with pharmaceutical clients from early product development through FDA commercial manufacturing with their patent-protected 3DP platform," said Philippe Tschopp, head of Business Development for Glatt Pharmaceutical Services, in the press release.
"The purpose of this agreement is to provide our clients more design options, which provide benefits such as modified release, bioavailability enhancement, taste masking, improved solubility, or API stabilization in a patient-preferred dosage form," said Aprecia CEO, Chris Gilmore, in the press release.